4SACKETT DL. Clinical Epidemilogy [ M ]. 2nd. Boston: Little, Brown and Company, 1991:297 - 299.
5The Uppsala Monitoring Centre(the UMC). Safety monitoring of medicinal products:guidelines for setting up and running a phar- macovigilance center[ EB/OL]. [ 2013 - 11 - 15 ]. http ://apps. who. int/medicinedocs/en/d/Jh2934e/15, html.
6EDWARDS IR, BIRIELL C. Harmonisation in pharmacovigi- lance[ J]. Drug Safety,1994,10(2) :93 -102.
7BEGAUD B, EVREUX JC, JOUGLARD J, et al. Unexpected ortoxic drug reaction assessment (imputation). Actualisation of the method used in France[ J]. Therapie, 1985,40 : 111 - 118.
8MEYBOOM RH, HEKSTER YA, EGBERTS AC, et al. Causal or casual? The role of causality assessment in pharmacovigilance [J]. Drug Safety,1997,17(6) :374 -389.
9MEYBOOM RH, EGBERTS AC, EDWARDS IR, et al. Princi- ples of signal detection in pharmacovigilanee [ J ]. Drug Safety, 1997,16(6) :355 - 365.
